scholarly journals Longitudinal Changes in Neuromelanin MRI Signal in Parkinson's Disease: A Progression Marker

2021 ◽  
Author(s):  
Rahul Gaurav ◽  
Lydia Yahia‐Cherif ◽  
Nadya Pyatigorskaya ◽  
Graziella Mangone ◽  
Emma Biondetti ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Longitudinal Changes ◽  
Progression Marker

scholarly journals Parkinson’s disease prognostic scores for progression of cognitive decline

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Galina Gramotnev ◽  
Dmitri K. Gramotnev ◽  
Alexandra Gramotnev
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cognitive Decline ◽  
Clinical Problem ◽  
Prognostic Scores ◽  
Clinical Biomarkers ◽  
Clinical Scores ◽  
Progression Marker ◽  
Drug Naïve ◽  
Relative Variable

AbstractClinical and biochemical diversity of Parkinson’s disease (PD) presents a major challenge for accurate diagnosis and prediction of its progression. We propose, develop and optimize PD clinical scores as efficient integrated progression biomarkers for prediction of the likely rate of cognitive decline in PD patients. We considered 269 drug-naïve participants from the Parkinson’s Progression Marker Initiative database, diagnosed with idiopathic PD and observed between 4 and 6 years. Nineteen baseline clinical and pathological measures were systematically considered. Relative variable importance and logistic regressions were used to optimize combinations of significant baseline measures as integrated biomarkers. Parkinson’s disease cognitive decline scores were designed as new clinical biomarkers using optimally categorized baseline measures. Specificities and sensitivities of the biomarkers reached ~93% for prediction of severe rate of cognitive decline (with more than 5 points decline in 4 years on the Montreal Cognitive Assessment scale), and up to ~73% for mild-to-moderate decline (between 1 and 5 points decline). The developed biomarkers and clinical scores could resolve the long-standing clinical problem about reliable prediction of PD progression into cognitive deterioration. The outcomes also provide insights into the contributions of individual clinical and pathological measures to PD progression, and will assist with better-targeted treatment regiments, stratification of clinical trial and their evaluation.

Longitudinal changes in speech and voice functions after subthalamic nucleus deep brain stimulation in Parkinson’s disease patients

2017 ◽  
Vol 381 ◽  
pp. 1042
Author(s):  
T. Tsuboi ◽  
H. Watanabe ◽  
Y. Tanaka ◽  
R. Ohdake ◽  
M. Hattori ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Deep Brain Stimulation ◽  
Subthalamic Nucleus ◽  
Brain Stimulation ◽  
Longitudinal Changes ◽  
Deep Brain

scholarly journals Early Parkinson's disease: Longitudinal changes in brain activity during sequence learning

2010 ◽  
Vol 37 (2) ◽  
pp. 455-460 ◽  
Author(s):  
Maren Carbon ◽  
Kathrin Reetz ◽  
M. Felice Ghilardi ◽  
Vijay Dhawan ◽  
David Eidelberg
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Sequence Learning ◽  
Brain Activity ◽  
Longitudinal Changes ◽  
Early Parkinson’S Disease

Longitudinal changes in CSF alpha-synuclein species reflect Parkinson's disease progression

2016 ◽  
Vol 31 (10) ◽  
pp. 1535-1542 ◽  
Author(s):  
Nour K. Majbour ◽  
Nishant N. Vaikath ◽  
Paolo Eusebi ◽  
Davide Chiasserini ◽  
Mustafa Ardah ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Disease Progression ◽  
Alpha Synuclein ◽  
Longitudinal Changes

scholarly journals Longitudinal Connectomes as a Candidate Progression Marker for Prodromal Parkinson’s Disease

2019 ◽  
Vol 12 ◽  
Author(s):  
Óscar Peña-Nogales ◽  
Timothy M. Ellmore ◽  
Rodrigo de Luis-García ◽  
Jessika Suescun ◽  
Mya C. Schiess ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Progression Marker

scholarly journals Longitudinal changes of cortical microstructure in Parkinson's disease assessed with T1 relaxometry

2017 ◽  
Vol 13 ◽  
pp. 405-414 ◽  
Author(s):  
Lucas Nürnberger ◽  
René-Maxime Gracien ◽  
Pavel Hok ◽  
Stephanie-Michelle Hof ◽  
Udo Rüb ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Longitudinal Changes ◽  
T1 Relaxometry

Longitudinal changes in movement-related functional MRI activity in Parkinson's disease patients

2021 ◽  
Author(s):  
Naomi Hannaway ◽  
Nicholas P. Lao-Kaim ◽  
Antonio Martín-Bastida ◽  
Andreas-Antonios Roussakis ◽  
Jonathan Howard ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Functional Mri ◽  
Longitudinal Changes

scholarly journals Progression marker of Parkinson’s disease: a 4-year multi-site imaging study

Brain ◽  
2017 ◽  
Vol 140 (8) ◽  
pp. 2183-2192 ◽  
Author(s):  
Roxana G Burciu ◽  
Edward Ofori ◽  
Derek B Archer ◽  
Samuel S Wu ◽  
Ofer Pasternak ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Imaging Study ◽  
Progression Marker

scholarly journals Longitudinal Changes in Cognition in Parkinson’s Disease with and without Dementia

2011 ◽  
Vol 31 (2) ◽  
pp. 98-108 ◽  
Author(s):  
David K. Johnson ◽  
James E. Galvin
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Longitudinal Changes

scholarly journals Step Length Is a Promising Progression Marker in Parkinson’s Disease

Sensors ◽  
2021 ◽  
Vol 21 (7) ◽  
pp. 2292
Author(s):  
Julius Welzel ◽  
David Wendtland ◽  
Elke Warmerdam ◽  
Robbin Romijnders ◽  
Morad Elshehabi ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Disease Progression ◽  
Step Length ◽  
Minor Effect ◽  
Progression Marker ◽  
Gait Parameters ◽  
Ancova Model ◽  
Length Changes ◽  
A Minor

Current research on Parkinson’s disease (PD) is increasingly concerned with the identification of objective and specific markers to make reliable statements about the effect of therapy and disease progression. Parameters from inertial measurement units (IMUs) are objective and accurate, and thus an interesting option to be included in the regular assessment of these patients. In this study, 68 patients with PD (PwP) in Hoehn and Yahr (H&Y) stages 1–4 were assessed with two gait tasks—20 m straight walk and circular walk—using IMUs. In an ANCOVA model, we found a significant and large effect of the H&Y scores on step length in both tasks, and only a minor effect on step time. This study provides evidence that from the two potentially most important gait parameters currently accessible with wearable technology under supervised assessment strategies, step length changes substantially over the course of PD, while step time shows surprisingly little change in the progression of PD. These results show the importance of carefully evaluating quantitative gait parameters to make assumptions about disease progression, and the potential of the granular evaluation of symptoms such as gait deficits when monitoring chronic progressive diseases such as PD.

Sign in / Sign up

Export Citation Format

Share Document